← 治験一覧に戻る
日本における滲出型加齢黄斑変性症(wAMD)患者の介護者の負担
基本情報
- NCT ID
- NCT02541084
- ステータス
- 完了
- 試験のフェーズ
- -
- 試験タイプ
- 観察
- 目標被験者数
- 72
- 治験依頼者名
- Bayer
概要
This study aims at investigation of the caregiver burden of Wet Age-related Macular Degeneration (wAMD) patients and at the assessment of how much of caregiver burden could be reduced in transitioning from Pro Re Nata to proactive therapy especially in real-life rural settings where public transportations are not readily available.
対象疾患
Wet Macular Degeneration
介入
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)(DRUG)
依頼者(Sponsor)
バイエル薬品株式会社(INDUSTRY)
Regeneron(INDUSTRY)